Passionate and precise, we bring life-saving medicines to people around the world. Building a new company. Engage, Empower, Enrich per costruire talentiScopri nella nuova brochure 2019 i valori, il costante impegno nella ricerca, e la dedizione al paziente che contraddistinguono il lavoro di BMS Italia.Bristol-Myers Squibb Italia destina ad AIMaC le donazioni raccolte durante la Country2Country 4Cancer 2019. Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Bristol-Myers Squibb Italia a supporto dell'iniziativa AIMaC. Our symbol, the hand, is a simple, universal expression of healing, of giving and receiving care. I fondi saranno utilizzati per il Servizio Informativo Nazionale in Oncologia. scopri di più I fondi saranno utilizzati per il Servizio Informativo Nazionale in Oncologia.Scopri la Piattaforma digitale di BMS creata come risorsa per pazienti, familiari, operatori sanitari e medici per avere informazioni sulle sperimentazioni clinicheIl Responsabile della Protezione dei Dati Personali del gruppo Bristol-Myers Squibb è raggiungibile al seguente indirizzo: It is a representation of humanity—the personal touch we bring to our work and the inspiration we draw from our patients and people.Our focus is always on people: the patients we work for, the workforce who discovers, develops and delivers our medications, and the partners with whom we collaborate.As a responsible global citizen, we will continue to take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to the patients who depend on us around the world.Every day, each of us works to improve outcomes for patients fighting serious diseases. “We realized that the deal with Celgene was so transformational that we were starting 2020 with a new company, a new BMS,” said Kathryn Metcalfe, EVP of corporate affairs at Bristol Myers Squibb.

The rebranding, with a new logo and website, is meant to unify the BMS and Celgene brands and reintroduce the company to the market post-acquisition. Together, we're building a better future for each other and the patients who need us most.Bristol Myers Squibb: Transforming patients’ lives through science As we build for the future, we’re uniting around a single, powerful vision.To reflect the transformation of our company, we have evolved our company brand. Bristol-Myers Squibb Italia destina ad AIMaC le donazioni raccolte durante la Country2Country 4Cancer 2019. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory.

At Bristol Myers Squibb, we’re inspired by a single vision—transforming patients’ lives through science. And we work together with compassion to improve outcomes for the patients who need us most.We bring a human touch to every treatment we pioneer. To reflect the transformation of our company, we have evolved our company brand. At Bristol Myers Squibb, we’re inspired by a single vision—transforming patients’ lives through science. Bristol Myers Squibb (NYSE: BMY) and Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb … On 6 March 2020, Bristol-Myers Squibb introduced a new logo. Passionate and precise, we bring life-saving medicines to people around the world. Abbracciamo una cultura inclusiva .

Siamo un'azienda biopharma globale, la cui mission è scoprire, sviluppare e rendere disponibili farmaci innovativi dedicati a pazienti che combattono contro gravi malattie.Un messaggio da Francesco Rocca, Presidente Nazionale della Croce Rossa Italiana “Voglio dire "grazie" a Bristol Myers Squibb e alla sua Fondazione che hanno sostenuto la Croce Rossa Italiana nell'emergenza Covid-19 attraverso un importante contributo economico e alla donazione di 23.400 mascherine per i nostri operatori e volontari..."Siamo impegnati a scoprire, sviluppare e rendere disponibili farmaci innovativi attraverso la ricerca, le collaborazioni e percorrendo opportunità strategiche di sviluppo aziendale.Al centro di ogni attività l’azienda pone l’attenzione alle esigenze dei pazienti, affinché possano accedere a terapie innovative nel più breve tempo possibile.Le nostre persone hanno esperienze diversificate.